SCHEMBL16906

SCHEMBL16906

CCOC(=O)C(Cc1cccnc1OC)NC(=O)CN

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 3/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41
OPRK1 P41145 2/20 0.40
NLRP3 Q96P20 1/20 0.40
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
ACACB O00763 1/20 0.39
SLC13A5 Q86YT5 1/20 0.38
HDAC6 Q9UBN7 4/20 0.38
HDAC1 Q13547 2/20 0.38
GAA P10253 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16907 1.00 CARM1 (0.41) CARM1MAPTTP53LMNATHRB
SCHEMBL18239 0.81 SCN9A (0.41) MAPTOPRK1HDAC6HDAC1KMT2A
SCHEMBL18238 0.81 SCN9A (0.41) MAPTOPRK1HDAC6HDAC1KMT2A
SCHEMBL17587 0.79 SLC13A5 (0.43) MAPTLMNANLRP3SLC13A5GAA
SCHEMBL17588 0.79 SLC13A5 (0.43) MAPTLMNANLRP3SLC13A5GAA
SCHEMBL6739005 0.78 NLRP3 (0.49) TP53LMNANLRP3ALDH1A1KMT2A
Hydrochloric Acid SCHEMBL3861695 0.77 TP53 (0.57) TP53GAARAB9AALDH1A1KMT2A
SCHEMBL11022951 0.76 TP53 (0.59) TP53LMNAGAARAB9AALDH1A1
SCHEMBL11155440 0.76 TP53 (0.59) TP53LMNAGAARAB9AALDH1A1
SCHEMBL17682 0.76 LOX (0.48) MAPTTP53NLRP3CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 CARM1 4120/4885MAPT 3958/4885TP53 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.